149 related articles for article (PubMed ID: 29605103)
1. Effects of adjunctive N-acetylcysteine on depressive symptoms: Modulation by baseline high-sensitivity C-reactive protein.
Porcu M; Urbano MR; Verri WA; Barbosa DS; Baracat M; Vargas HO; Machado RCBR; Pescim RR; Nunes SOV
Psychiatry Res; 2018 May; 263():268-274. PubMed ID: 29605103
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.
Raison CL; Rutherford RE; Woolwine BJ; Shuo C; Schettler P; Drake DF; Haroon E; Miller AH
JAMA Psychiatry; 2013 Jan; 70(1):31-41. PubMed ID: 22945416
[TBL] [Abstract][Full Text] [Related]
3. A Double-Blind, Randomized, Placebo-Controlled Study of Aspirin and N-Acetylcysteine as Adjunctive Treatments for Bipolar Depression.
Bauer IE; Green C; Colpo GD; Teixeira AL; Selvaraj S; Durkin K; Zunta-Soares GB; Soares JC
J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30549489
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
5. A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo.
Berk M; Turner A; Malhi GS; Ng CH; Cotton SM; Dodd S; Samuni Y; Tanious M; McAulay C; Dowling N; Sarris J; Owen L; Waterdrinker A; Smith D; Dean OM
BMC Med; 2019 Jan; 17(1):18. PubMed ID: 30678686
[TBL] [Abstract][Full Text] [Related]
6. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.
Yang C; Bosker FJ; Li J; Schoevers RA
BMC Psychiatry; 2018 Sep; 18(1):279. PubMed ID: 30176835
[TBL] [Abstract][Full Text] [Related]
7. Adjunctive N-acetylcysteine in depression: exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor.
Hasebe K; Gray L; Bortolasci C; Panizzutti B; Mohebbi M; Kidnapillai S; Spolding B; Walder K; Berk M; Malhi G; Dodd S; Dean OM
Acta Neuropsychiatr; 2017 Dec; 29(6):337-346. PubMed ID: 28318471
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial.
Berk M; Dean OM; Cotton SM; Jeavons S; Tanious M; Kohlmann K; Hewitt K; Moss K; Allwang C; Schapkaitz I; Robbins J; Cobb H; Ng F; Dodd S; Bush AI; Malhi GS
J Clin Psychiatry; 2014 Jun; 75(6):628-36. PubMed ID: 25004186
[TBL] [Abstract][Full Text] [Related]
9. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study.
Rapaport MH; Nierenberg AA; Schettler PJ; Kinkead B; Cardoos A; Walker R; Mischoulon D
Mol Psychiatry; 2016 Jan; 21(1):71-9. PubMed ID: 25802980
[TBL] [Abstract][Full Text] [Related]
10. The effect of treatment with N-acetylcysteine on the serum levels of C-reactive protein and interleukin-6 in patients on hemodialysis.
Saddadi F; Alatab S; Pasha F; Ganji MR; Soleimanian T
Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):66-72. PubMed ID: 24434384
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein and fibrinogen in non-obstructive coronary artery disease as related to depressive symptoms and anxiety: findings from the TweeSteden Mild Stenosis Study (TWIST).
Mommersteeg PM; Meeuwis SH; Denollet J; Widdershoven JW; Aarnoudse W; Westerhuis BL; Kop WJ
J Psychosom Res; 2014 Nov; 77(5):426-9. PubMed ID: 25307791
[TBL] [Abstract][Full Text] [Related]
12. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
[TBL] [Abstract][Full Text] [Related]
13. A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial to assess the efficacy of adjunctive N-Acetylcysteine for treatment-resistant PTSD: a study protocol.
Maier A; Dharan A; Oliver G; Berk M; Redston S; Back SE; Kalivas P; Ng C; Kanaan RA
BMC Psychiatry; 2020 Aug; 20(1):397. PubMed ID: 32762663
[TBL] [Abstract][Full Text] [Related]
14. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
15. N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial.
Berk M; Copolov DL; Dean O; Lu K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Bush AI
Biol Psychiatry; 2008 Sep; 64(6):468-75. PubMed ID: 18534556
[TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
Hanefeld M; Marx N; Pfützner A; Baurecht W; Lübben G; Karagiannis E; Stier U; Forst T
J Am Coll Cardiol; 2007 Jan; 49(3):290-7. PubMed ID: 17239709
[TBL] [Abstract][Full Text] [Related]
17. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
18. Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder.
Tomko RL; Baker NL; Hood CO; Gilmore AK; McClure EA; Squeglia LM; McRae-Clark AL; Sonne SC; Gray KM
Psychopharmacology (Berl); 2020 Feb; 237(2):479-490. PubMed ID: 31712969
[TBL] [Abstract][Full Text] [Related]
19. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
[TBL] [Abstract][Full Text] [Related]
20. Plasma C-reactive protein levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment.
Edberg D; Hoppensteadt D; Walborn A; Fareed J; Sinacore J; Halaris A
J Psychiatr Res; 2018 Jul; 102():1-7. PubMed ID: 29554535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
